Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Dr. R Ananthanarayanan appointed as the new CEO & Managing Director of Strides

Posted On: 2020-01-08 20:48:27


Strides Pharma Science Limited (Strides) today announced that the Board of Directors (Board) of the Company have appointed Dr. R Ananthanarayanan as Chief Executive Officer (CEO) and Managing Director (MD) of Strides effective January 09, 2020.

Dr. R Ananthanarayanan (Ananth) will succeed Arun Kumar, Founder, and the incumbent CEO & MD of the Company. Arun will transition his active responsibilities at Strides by the financial year ending March 31, 2020, and will step into a strategic role as Chairman of the Board with effect from April 01, 2020.

Ananth brings with him over three decades of top pedigree global pharmaceutical experience across both the technical and commercial functions. Until recently, Ananth was the Global Chief Operating Officer at Cipla Limited, where he was responsible for the company's generics business in regulated markets and branded generics in emerging markets. He was also driving their API business, biosimilars, complex drug-device combinations, including 505(b)(2) products.

Prior to Cipla, Ananth was the President & CEO of Global APIs, Biologics, & Medis Generics B2B division at Teva Pharmaceutical Industries Ltd in the US, managing multi-billion P&L responsibility. He has also held leadership roles at Dr. Reddy's Laboratories, Piramal Healthcare (Formerly Nicholas Piramal), Galpharm International, UK (Acquired by Perrigo Group), and Zydus Cadila.

Ananth is a Graduate in Pharmaceutical Sciences and earned his Ph.D. in Pharmaceutical Technology from the University of Mumbai, India. He has also been a member of the Board of Advisors at the School of Pharmacy and Health Sciences at Fairleigh Dickinson University, New Jersey.

Ananth's appointment at Strides comes at the time when the company has concluded its reset strategy to drive profitable future growth on the back of a stronger balance sheet. The Board strongly believes that Ananth's exceptional global techno-commercial experience and leadership stature in managing the P&Ls of large global pharmaceutical companies will multiply the company's commitment to creating perpetual value for all its stakeholders.

Expressing confidence in the Board's choice , Arun Kumar,remarked, "Having founded Strides and led the company for close to 30 years, I believe the time is right for me to step aside and have Ananth lead it to greater heights. Ananth brings in the right balance of technical and commercial expertise, and I am confident that Strides will significantly benefit from his leadership experience, industry perspective, technical knowledge, and business acumen. As he takes on the mantle of Strides, I will now move to a more strategic role as the Chairman of the Board and will dedicate time to Strides' newly announced investments in Biotech and sterile injectables."

Dr. R Ananthanarayanan, the new CEO & MD of Strides, commented, "It's my privilege and honor to take over as the CEO & MD of Strides, and I would like to appreciate the confidence reposed in me by Arun and the Board. These are exciting times for Strides, and I look forward to partner with all the global colleagues to ensure successful realization of the Strides strategic objectives while ensuring that we consistently deliver quality medicines to all our patients globally."

Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.382 as compared to the previous close of Rs. 375.4. The total number of shares traded during the day was 58063 in over 1374 trades.

The stock hit an intraday high of Rs. 382 and intraday low of 369.2. The net turnover during the day was Rs. 21780724.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Abbott India Ltd posts Rs. 180.35 crore PAT in Q1FY21

FDC Limited to acquire further stake in South Africa firm

Energy Development Company Ltd board recommends dividend of Rs. 0.50

Hero MotoCorp donates unique first responder vehicles to Civil Hospital, Gurugram

Mirchi revenues fall 72%, but market share rises to 33%

FDC Ltd board approves buy-back at Rs. 450

Gujarat Themis Biosyn Ltd board to approve quarterly results on Aug 13, 2020

Ravileela Granites Ltd Q1 consolidated net profit up at Rs. 0.74 crore

Indowind Energy Ltd posts consolidated PAT of Rs. 3.40 crore in Q1

FDC Ltd reports consolidated PAT of Rs. 91.72 crore in Q1FY21

Mercury Laboratories Ltd Q1 PAT at Rs. 0.96 crore

BATA India Ltd reports loss of Rs. 100.88 crore in Q1FY21

Seshasayee Paper & Boards Ltd Q1FY21 consolidated net profit lower at Rs. 19.30 crore

ANUH Pharma Ltd board approves 1:1 bonus issue

Siemens Limited announces Q3 FY 2020 results, Performance impacted due to COVID-19

WINTAC Ltd Q1 loss at Rs. 0.3158 crore

Sudarshan Chemical Industries Ltd posts Rs. 18.19 crore consolidated PAT in Q1FY21

CIPLA Ltd Q1FY21 consolidated PAT up at Rs. 577.91 crore

DIC India Ltd Q2CY20 PAT soars on exceptional income

Andhra Paper Ltd reports loss in Q1FY21

Natural Capsules Ltd Q1FY21 net profit surges to Rs. 2.48 crore

The Shipping Corporation of India Ltd posts consolidated PAT of Rs. 336.87 crore in Q1FY21

ANUH Pharma Ltd Q1FY21 net profit up at Rs. 16.72 crore

RAMCO Industries Ltd Q1FY21 consolidated net profit rises to Rs. 61.83 crore

Container Corporation of India Ltd Q1FY21 consolidated PAT slides to Rs. 60.61 crore

Automotive Axles Ltd Q1 loss at Rs. 2.30 crore

Morganite Crucible India Ltd posts loss of Rs. 0.67 crore in Q1

Monte Carlo Fashions Ltd Q1FY21 loss at Rs. 13.53 crore

Nucleus Software Exports Ltd Q1FY21 consolidated PAT surges to Rs. 36.33 crore

Kesar Enterprises Ltd Q4FY20 PAT surges to Rs. 36.90 crore

Murugappa group firm to invest in CG Power and Industrial Solutions Ltd

Zensar to host Digital Foundation Services (DFS) Virtual Analyst and Advisor Conclave

JK Agri Genetics Ltd to raise funds upto Rs. 50 crore

Apollo Hopsital asks for 50% rent waiver

Shree Renuka Sugars Ltd to issue 2,11,670,481 Equity Shares at Rs. 8.74

REC Ltd Q1FY21 consolidated PAT soars to Rs. 1845.30 crore

Amara Raja Batteries Ltd Q1FY21 consolidated net profit declines to Rs. 62.49 crore

Aditya Birla Capital Ltd Q1FY21 consolidated net profit at Rs. 198.38 crore

Mangalam Cement Ltd posts net profit of Rs. 13.79 crore in Q1

Kaycee Industries Ltd Q1 loss at Rs. 0.20 crore

Nath Bio-Genes India Ltd Q1FY21 PAT rises to Rs. 41.25 crore

Birla Corporation Ltd reports earnings for Q1FY21

JK Agri Genetics Ltd Q1 PAT zooms to Rs. 19.20 crore

Finolex Industries Ltd posts consolidated PAT of Rs. 56.72 crore in Q1FY21

Shreyans Industries Ltd posts Rs. 6.77 crore PAT in Q1

Adani Transmission Ltd Q1FY21 consolidated PAT higher at Rs. 383.55 crore

Targeting the significant shift to Spiritual-Religious Tourism, Thomas Cook India & SOTC launch Ramayana Trails

Rane Madras Ltd announces Q1FY21 results

BHEL commences Civil Works at 660 MW Sagardighi Supercritical Thermal Power Plant in West Bengal

Equitas Small Finance Bank Limited is now the official retail banking partner of Chennai Super Kings







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019